Zai Lab's Phase 3 pivotal clinical study PANOVA-3 completes the first patient enrollment in Greater China

Recently, Zai Lab announced that PANOVA-3, a pivotal Phase 3 clinical study of tumor electric field therapy for pancreatic cancer, completed the first patient enrollment in Greater China
.
PANOVA-3 is a global, open-label, randomized phase III study to evaluate tumor field therapy in combination with gemcitabine and nab-paclitaxel as first-line treatment of unresectable locally advanced pancreatic cancer
.
The study is expected to enroll approximately 556 patients
.
The primary endpoint was overall survival (OS)
.
Secondary endpoints included progression-free survival (PFS), local progression-free survival, objective response rate (ORR), one-year survival, quality of life, pain-free survival, resectable rate, and toxicity
.
Tumor electric field therapy (TTFields for short) is a device that suppresses tumor cells
.
Basic scientific research on tumor field therapy spans two decades.
To date, tumor field therapy has shown consistent anti-mitotic effects in all preclinical studies
.
Tumor electric field therapy is mainly used in combination with other standard treatment regimens
.
There is growing in vitro evidence that tumor electric field therapy can be widely used in combination with cancer treatment regimens, such as radiotherapy, some chemotherapy and immunotherapy
.
In clinical studies and commercialization, tumor electric field therapy has not shown systemic toxicity, and the common side effect is mild to moderate skin inflammation
.
The global R&D program for Tumor Field Therapy includes pre-clinical collaborations and extensive clinical studies at all stages, including pivotal Phase III clinical studies across multiple tumor types
.
To date, more than 20,000 cancer patients have been treated with tumor fields
.